 | • レポートコード：MRC2-11QY01539 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は特発性血小板減少性紫斑病（ITP）治療薬のグローバル市場について調査・分析したレポートです。種類別（コルチコステロイド、静脈内免疫グロブリン（IVIG）、抗D免疫グロブリン、トロンボポエチン受容体作動薬（TPO-RA）、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別特発性血小板減少性紫斑病（ITP）治療薬の競争状況、市場シェア ・世界の特発性血小板減少性紫斑病（ITP）治療薬市場：種類別市場規模 2015年-2020年（コルチコステロイド、静脈内免疫グロブリン（IVIG）、抗D免疫グロブリン、トロンボポエチン受容体作動薬（TPO-RA）、その他） ・世界の特発性血小板減少性紫斑病（ITP）治療薬市場：種類別市場規模予測 2021年-2026年（コルチコステロイド、静脈内免疫グロブリン（IVIG）、抗D免疫グロブリン、トロンボポエチン受容体作動薬（TPO-RA）、その他） ・世界の特発性血小板減少性紫斑病（ITP）治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の特発性血小板減少性紫斑病（ITP）治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の特発性血小板減少性紫斑病（ITP）治療薬市場分析：米国、カナダ ・ヨーロッパの特発性血小板減少性紫斑病（ITP）治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの特発性血小板減少性紫斑病（ITP）治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の特発性血小板減少性紫斑病（ITP）治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの特発性血小板減少性紫斑病（ITP）治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Roch、Amgen Inc、Grifols Biologicals Inc.、GlaxoSmithKline Plc ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
ITP (idiopathic thrombocytopenic purpura) is a rare disease with low affliction rates. This disease leads to excessive bruising or bleeding due to the lack of blood platelets. It is also known as immune thrombocytopenia and can affect children and adults alike.
Increasing demand for combination therapies therapy is expected to fuel the future growth of the ITP therapeutics market. Clinical evidence suggest that combination therapies entail relatively lower side effects, are cost effective and display higher response rates in patients.
Market Analysis and Insights: Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market
The global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market size is projected to reach US$ 448.9 million by 2026, from US$ 433.5 million in 2020, at a CAGR of 3.3%% during 2021-2026.
Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Scope and Market Size
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market is segmented into
Corticosteroids
Intravenous Immunoglobulin (IVIG)
Anti-D Immunoglobulin
Thrombopoietin Receptor Agonists (TPO-RA)
Others
Segment by Application, the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market is segmented into
Hospitals
Clincs
Others
Regional and Country-level Analysis
The Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market is analysed and market size information is provided by regions (countries).
The key regions covered in the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share Analysis
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics business, the date to enter into the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market, Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics product introduction, recent developments, etc.
The major vendors covered:
Roch
Amgen Inc
Grifols Biologicals Inc.
GlaxoSmithKline Plc
…
1 Study Coverage
1.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Introduction
1.2 Market Segments
1.3 Key Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth Rate by Type
1.4.2 Corticosteroids
1.4.3 Intravenous Immunoglobulin (IVIG)
1.4.4 Anti-D Immunoglobulin
1.4.5 Thrombopoietin Receptor Agonists (TPO-RA)
1.4.6 Others
1.5 Market by Application
1.5.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth Rate by Application
1.5.2 Hospitals
1.5.3 Clincs
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size, Estimates and Forecasts
2.1.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue 2015-2026
2.1.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales 2015-2026
2.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Competitor Landscape by Players
3.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Manufacturers
3.1.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Manufacturers (2015-2020)
3.1.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Manufacturers (2015-2020)
3.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Manufacturers
3.2.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Manufacturers (2015-2020)
3.2.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue in 2019
3.2.5 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Price by Manufacturers
3.4 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Manufacturing Base Distribution, Product Types
3.4.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Type
3.4.3 Date of International Manufacturers Enter into Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2015-2020)
4.1.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Type (2015-2020)
4.1.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2015-2020)
4.1.3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Forecast by Type (2021-2026)
4.2.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Forecast by Type (2021-2026)
4.2.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Forecast by Type (2021-2026)
4.2.3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2015-2020)
5.1.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Application (2015-2020)
5.1.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2015-2020)
5.1.3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Price by Application (2015-2020)
5.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Forecast by Application (2021-2026)
5.2.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Forecast by Application (2021-2026)
5.2.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Forecast by Application (2021-2026)
5.2.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Price Forecast by Application (2021-2026)
6 North America
6.1 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Country
6.1.1 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Country
6.1.2 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Facts & Figures by Type
6.3 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Facts & Figures by Application
7 Europe
7.1 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Country
7.1.1 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Country
7.1.2 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Facts & Figures by Type
7.3 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Region
8.1.1 Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Region
8.1.2 Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Facts & Figures by Type
8.3 Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Facts & Figures by Application
9 Latin America
9.1 Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Country
9.1.1 Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Country
9.1.2 Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Facts & Figures by Type
9.3 Central & South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Country
10.1.1 Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Country
10.1.2 Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Facts & Figures by Type
10.3 Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Facts & Figures by Application
11 Company Profiles
11.1 Roch
11.1.1 Roch Corporation Information
11.1.2 Roch Description and Business Overview
11.1.3 Roch Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Products Offered
11.1.5 Roch Related Developments
11.2 Amgen Inc
11.2.1 Amgen Inc Corporation Information
11.2.2 Amgen Inc Description and Business Overview
11.2.3 Amgen Inc Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Products Offered
11.2.5 Amgen Inc Related Developments
11.3 Grifols Biologicals Inc.
11.3.1 Grifols Biologicals Inc. Corporation Information
11.3.2 Grifols Biologicals Inc. Description and Business Overview
11.3.3 Grifols Biologicals Inc. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Products Offered
11.3.5 Grifols Biologicals Inc. Related Developments
11.4 GlaxoSmithKline Plc
11.4.1 GlaxoSmithKline Plc Corporation Information
11.4.2 GlaxoSmithKline Plc Description and Business Overview
11.4.3 GlaxoSmithKline Plc Sales, Revenue and Gross Margin (2015-2020)
11.4.4 GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Products Offered
11.4.5 GlaxoSmithKline Plc Related Developments
11.1 Roch
11.1.1 Roch Corporation Information
11.1.2 Roch Description and Business Overview
11.1.3 Roch Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Products Offered
11.1.5 Roch Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Estimates and Projections by Region
12.1.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Forecast by Regions 2021-2026
12.1.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Forecast by Regions 2021-2026
12.2 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Forecast (2021-2026)
12.2.1 North America: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Forecast (2021-2026)
12.2.2 North America: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Forecast (2021-2026)
12.2.3 North America: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Forecast by Country (2021-2026)
12.3 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Forecast (2021-2026)
12.3.1 Europe: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Forecast (2021-2026)
12.3.2 Europe: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Forecast (2021-2026)
12.3.3 Europe: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Forecast by Region (2021-2026)
12.5 Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Forecast (2021-2026)
12.5.1 Latin America: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Forecast (2021-2026)
12.5.2 Latin America: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Forecast (2021-2026)
12.5.3 Latin America: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Segments
Table 2. Ranking of Global Top Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Corticosteroids
Table 5. Major Manufacturers of Intravenous Immunoglobulin (IVIG)
Table 6. Major Manufacturers of Anti-D Immunoglobulin
Table 7. Major Manufacturers of Thrombopoietin Receptor Agonists (TPO-RA)
Table 8. Major Manufacturers of Others
Table 9. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth Rate by Application 2020-2026 (K Units)
Table 10. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 11. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Regions 2015-2020 (K Units)
Table 12. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Regions (2015-2020)
Table 13. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Manufacturers (2015-2020) (K Units)
Table 15. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Share by Manufacturers (2015-2020)
Table 16. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics as of 2019)
Table 18. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Price (2015-2020) (USD/Unit)
Table 21. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Type
Table 23. Date of International Manufacturers Enter into Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Type (2015-2020) (K Units)
Table 26. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Share by Type (2015-2020)
Table 27. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Type (2015-2020)
Table 29. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 30. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Application (2015-2020) (K Units)
Table 31. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Share by Application (2015-2020)
Table 32. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Country (2015-2020) (K Units)
Table 33. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Country (2015-2020)
Table 34. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Country (2015-2020)
Table 36. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Type (2015-2020) (K Units)
Table 37. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Type (2015-2020)
Table 38. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Application (2015-2020) (K Units)
Table 39. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Application (2015-2020)
Table 40. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Country (2015-2020) (K Units)
Table 41. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Country (2015-2020)
Table 42. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Country (2015-2020)
Table 44. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Type (2015-2020) (K Units)
Table 45. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Type (2015-2020)
Table 46. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Application (2015-2020) (K Units)
Table 47. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Region (2015-2020) (K Units)
Table 49. Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Type (2015-2020) (K Units)
Table 53. Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Application (2015-2020) (K Units)
Table 55. Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Application (2015-2020)
Table 56. Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Country (2015-2020) (K Units)
Table 57. Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Country (2015-2020)
Table 60. Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Type (2015-2020) (K Units)
Table 61. Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Type (2015-2020)
Table 62. Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Application (2015-2020) (K Units)
Table 63. Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Country (2015-2020) (K Units)
Table 65. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Type (2015-2020) (K Units)
Table 69. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Application (2015-2020) (K Units)
Table 71. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Application (2015-2020)
Table 72. Roch Corporation Information
Table 73. Roch Description and Major Businesses
Table 74. Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 75. Roch Product
Table 76. Roch Recent Development
Table 77. Amgen Inc Corporation Information
Table 78. Amgen Inc Description and Major Businesses
Table 79. Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 80. Amgen Inc Product
Table 81. Amgen Inc Recent Development
Table 82. Grifols Biologicals Inc. Corporation Information
Table 83. Grifols Biologicals Inc. Description and Major Businesses
Table 84. Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 85. Grifols Biologicals Inc. Product
Table 86. Grifols Biologicals Inc. Recent Development
Table 87. GlaxoSmithKline Plc Corporation Information
Table 88. GlaxoSmithKline Plc Description and Major Businesses
Table 89. GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 90. GlaxoSmithKline Plc Product
Table 91. GlaxoSmithKline Plc Recent Development
Table 92. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Forecast by Regions (2021-2026) (K Units)
Table 93. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share Forecast by Regions (2021-2026)
Table 94. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 95. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share Forecast by Regions (2021-2026)
Table 96. North America: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Forecast by Country (2021-2026) (K Units)
Table 97. North America: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 98. Europe: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Forecast by Country (2021-2026) (K Units)
Table 99. Europe: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 100. Asia Pacific: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Forecast by Region (2021-2026) (K Units)
Table 101. Asia Pacific: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Forecast by Region (2021-2026) (US$ Million)
Table 102. Latin America: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Forecast by Country (2021-2026) (K Units)
Table 103. Latin America: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 104. Middle East and Africa: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Forecast by Country (2021-2026) (K Units)
Table 105. Middle East and Africa: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 106. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 107. Key Challenges
Table 108. Market Risks
Table 109. Main Points Interviewed from Key Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Players
Table 110. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Customers List
Table 111. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Distributors List
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Picture
Figure 2. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Type in 2020 & 2026
Figure 3. Corticosteroids Product Picture
Figure 4. Intravenous Immunoglobulin (IVIG) Product Picture
Figure 5. Anti-D Immunoglobulin Product Picture
Figure 6. Thrombopoietin Receptor Agonists (TPO-RA) Product Picture
Figure 7. Others Product Picture
Figure 8. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Application in 2020 & 2026
Figure 9. Hospitals
Figure 10. Clincs
Figure 11. Others
Figure 12. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Report Years Considered
Figure 13. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size 2015-2026 (US$ Million)
Figure 14. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales 2015-2026 (K Units)
Figure 15. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Region (2015-2020)
Figure 17. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Region in 2019
Figure 18. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Region (2015-2020)
Figure 19. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Region in 2019
Figure 20. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue in 2019
Figure 22. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Type (2015-2020)
Figure 24. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Type in 2019
Figure 25. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Type (2015-2020)
Figure 26. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Type in 2019
Figure 27. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Price Range (2015-2020)
Figure 28. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Application (2015-2020)
Figure 29. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Application in 2019
Figure 30. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Application (2015-2020)
Figure 31. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Application in 2019
Figure 32. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate 2015-2020 (K Units)
Figure 33. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 34. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Country in 2019
Figure 35. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Country in 2019
Figure 36. U.S. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 37. U.S. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Canada Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 39. Canada Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Type in 2019
Figure 41. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Application in 2019
Figure 42. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate 2015-2020 (K Units)
Figure 43. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Country in 2019
Figure 45. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Country in 2019
Figure 46. Germany Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 47. Germany Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. France Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 49. France Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. U.K. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 51. U.K. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Italy Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 53. Italy Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Russia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 55. Russia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Type in 2019
Figure 57. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Application in 2019
Figure 58. Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate 2015-2020 (K Units)
Figure 59. Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 60. Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Region in 2019
Figure 61. Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Region in 2019
Figure 62. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 63. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Japan Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 65. Japan Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. South Korea Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 67. South Korea Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. India Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 69. India Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Australia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 71. Australia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Taiwan Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 73. Taiwan Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Indonesia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 75. Indonesia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Thailand Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 77. Thailand Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Malaysia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 79. Malaysia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Philippines Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 81. Philippines Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Vietnam Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 83. Vietnam Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Type in 2019
Figure 85. Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Application in 2019
Figure 86. Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate 2015-2020 (K Units)
Figure 87. Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 88. Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Country in 2019
Figure 89. Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Country in 2019
Figure 90. Mexico Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 91. Mexico Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Brazil Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 93. Brazil Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Argentina Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 95. Argentina Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Type in 2019
Figure 97. Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Application in 2019
Figure 98. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate 2015-2020 (K Units)
Figure 99. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Country in 2019
Figure 101. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Country in 2019
Figure 102. Turkey Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 103. Turkey Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 105. Saudi Arabia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 107. U.A.E Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Type in 2019
Figure 109. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Application in 2019
Figure 110. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 111. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 113. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 115. Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 117. Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 119. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Porter's Five Forces Analysis
Figure 121. Channels of Distribution
Figure 122. Distributors Profiles
Figure 123. Bottom-up and Top-down Approaches for This Report
Figure 124. Data Triangulation
Figure 125. Key Executives Interviewed
免疫性血小板減少性紫斑病治療薬の世界市場（～2026年） Market Analysis and Insights: Global Immune Thrombocytopenic Purpura Therapeutics Market The global Immune Thrombocytopenic Purpura Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Immune Thrombocytopenic P…- 血栓性血小板減少性紫斑病治療の世界市場（～2026年） Market Analysis and Insights: Global Thrombotic Thrombocytopenic Purpura Treatment Market The global Thrombotic Thrombocytopenic Purpura Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Thrombotic Thrombocytop…
- 紫斑治療の世界市場（～2026年） Purpura is a condition of red or purple discolored spots on the skin that do not blanch on applying pressure. The globally market for purpura treatment is one of the steady growing markets. Purpura occurs when the blood vessels and blood pools under the human skin, result in purple spots on the skin…
- 特発性頭蓋内圧亢進症治療薬の世界市場（～2026年） A drug used to treat idiopathic intracranial hypertension. Market Analysis and Insights: Global Idiopathic Intracranial Hypertension Therapeutics Market The global Idiopathic Intracranial Hypertension Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020,…
- 慢性特発性骨髄線維症の世界市場（～2026年） Idiopathic myelofibrosis is a chronic myelo-proliferative disorder and characterized by abnormal mutation of stem cells. This abnormal mutation of stem cells and excessive production of platelets result in development of fibrous tissues within the bone-marrow. This factor would ultimately negatively…